Barclays PLC Has $1.05 Million Holdings in Annexon, Inc. (NASDAQ:ANNX)

Barclays PLC boosted its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 212.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 177,765 shares of the company’s stock after buying an additional 120,789 shares during the period. Barclays PLC owned about 0.17% of Annexon worth $1,052,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Point72 Asset Management L.P. grew its stake in shares of Annexon by 16.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock valued at $29,346,000 after buying an additional 832,617 shares in the last quarter. Point72 Europe London LLP bought a new stake in shares of Annexon in the 2nd quarter valued at approximately $1,150,000. Charles Schwab Investment Management Inc. grew its stake in shares of Annexon by 221.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock valued at $4,335,000 after buying an additional 504,656 shares in the last quarter. FMR LLC grew its stake in shares of Annexon by 3.2% in the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after buying an additional 262,229 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Annexon by 116.6% in the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after buying an additional 2,068,294 shares in the last quarter.

Annexon Trading Down 1.2 %

ANNX opened at $5.13 on Tuesday. Annexon, Inc. has a 1-year low of $3.86 and a 1-year high of $8.40. The stock has a market capitalization of $546.83 million, a price-to-earnings ratio of -4.89 and a beta of 1.10. The business has a 50 day moving average of $5.90 and a 200-day moving average of $5.94.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ANNX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Annexon in a research report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $15.80.

Insider Activity at Annexon

In related news, EVP Ted Yednock sold 5,408 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total value of $40,073.28. Following the completion of the transaction, the executive vice president now directly owns 71,365 shares in the company, valued at approximately $528,814.65. This represents a 7.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.67% of the stock is currently owned by corporate insiders.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.